查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869710

美國避孕產品市場規模、佔有率和趨勢分析報告：產品和細分市場預測（2025-2033）

U.S. Contraceptive Market Size, Share & Trends Analysis Report By Product, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國避孕產品市場規模及趨勢：

預計到 2024 年，美國避孕產品市場價值將達到 80.8 億美元，到 2033 年將達到 123.7 億美元。

預計2025年至2033年間，該市場將以4.88%的複合年成長率成長。現代避孕產品的使用率不斷提高，以及青少年和年輕人對性健康和計劃生育的意識提升，是推動這一成長的主要因素。此外，政府計畫也正在擴大避孕產品的取得途徑，有助於預防青少年意外懷孕。

女性避孕健康領域的持續創新

隨著人們對可靠替代方案的需求、意識和偏好不斷提高，各公司致力於提供安全、有效和長期的避孕選擇，以滿足世界各地女性不斷變化的需求，從而推動了相關技術的重大進步和新產品的推出。

Anyloring：擴大避孕選擇

2023年10月，Xiromed LLC推出了Eniloring（依托孕烯/炔雌醇陰道環），它是NuvaRing的學名藥。該產品提供長效避孕效果，是Xiromed公司廣泛的女性藥品產品線的重要擴展，該產品線還包括口服避孕藥和經皮凝膠。

Xiromed執行長Rob Spina就此次發布的重要意義發表了評論：

“Eniloring的上市標誌著我們在成為美國領先的女性健康保健產品學名藥供應商的征程中邁出了激動人心的一步。我們致力於為美國患者拓展和改善避孕選擇。”

Eniloring 由西班牙萊昂的 Laboratorios Leon Pharma 生產，體現了 Siromed 致力於利用尖端技術的承諾，也是 Insad Pharma 致力於推動女性健康解決方案的一部分。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 法律規範
  • 商業環境分析工具
    • 產業分析—波特五力分析
    • PESTEL 分析

第4章 產品業務分析

  • 美國避孕產品市場：產品差異分析
  • 美國避孕產品市場：產品細分儀表板
  • 2024年及2033年產品趨勢及市佔率分析
  • 依產品
  • 藥片
  • 子宮內避孕器（IUD）
    • 子宮內激素裝置
    • 非荷爾蒙子宮內避孕器
  • 保險套
    • 男用保險套
    • 女性用保險套
  • 避孕環
  • 皮下植入
  • 注射
  • 其他

第5章 競爭情勢

  • 公司分類
  • 企業市場分析，2024年
  • 策略規劃
    • 併購
    • 夥伴關係與合作
    • 新產品上市
    • 其他
  • 公司簡介
    • Church &Dwight Co., Inc.
    • Reckitt Benckiser Group Plc
    • Organon Group of Companies
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
    • The Cooper Companies, Inc.
    • Agile Therapeutics
    • Mayer Laboratories, Inc.
    • Mayne Pharma Group Limited.
    • Bayer AG
    • Afaxys, Inc.
    • AbbVie
    • Gedeon Richter
Product Code: GVR-2-68038-702-5

U.S. Contraceptive Market Size & Trends:

The U.S. contraceptive market size was valued at USD 8.08 billion in 2024 and is expected to reach USD 12.37 billion by 2033, growing at a CAGR of 4.88% from 2025 to 2033. The increase in the use of modern contraceptives and the rise in awareness among adolescents and young people about sexual health and family planning are key factors driving growth. Moreover, government programs have led to an increase in access to contraceptives that help prevent unwanted pregnancies in teenagers.

Continued Innovation in Women's Contraceptive Health

With the increasing demand, awareness, and preference for reliable alternatives, companies are looking forward to offering safe, effective, and long-term contraceptive options to meet the evolving needs of women worldwide, leading to notable advancements and product launches.

EnilloRing: Expanding Contraceptive Choices

In October 2023, Xiromed LLC introduced EnilloRing (etonogestrel/ethinyl estradiol vaginal ring), a generic alternative to NuvaRing. This product offers long-lasting contraceptive protection and marks an important expansion of Xiromed's extensive range of women's health medications, which also feature oral contraceptives and transdermal gels.

Rob Spina, CEO of Xiromed, highlighted the impact of this launch:

"The launch of EnilloRing is an exciting milestone in Xiromed's journey to becoming a leading generic provider of women's healthcare products in the United States. We are committed to broadening and growing the availability of contraceptive options for U.S. patients."

Manufactured at Laboratorios Leon Pharma SAU in Leon, Spain, EnilloRing underscores Xiromed's dedication to leveraging cutting-edge technologies as part of Insud Pharma's commitment to advancing women's health solutions.

U.S. Contraceptive Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. contraceptive market report based on product.

  • Product Outlook (Revenue, USD Billion, 2021 - 2033)
  • Pills
  • Intrauterine Devices (IUD)
    • Hormonal IUD
    • Nonhormonal IUD
  • Condoms
    • Male Condoms
    • Female Condoms
  • Vaginal Ring
  • Subdermal Implants
  • Injectable
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Contraceptive Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Product segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis

Chapter 4. Product Business Analysis

  • 4.1. U.S. Contraceptive Market: Product Movement Analysis
  • 4.2. U.S. Contraceptive Market: Product Segment Dashboard
  • 4.3. Product Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Contraceptive Market Estimates & Forecast, by Product
  • 4.5. Pills
    • 4.5.1. Pills Market, 2021 - 2033 (USD Million)
  • 4.6. Intrauterine Devices (IUD)
    • 4.6.1. Intrauterine Devices (IUD) Market, 2021 - 2033 (USD Million)
    • 4.6.2. Hormonal IUD
      • 4.6.2.1. Hormonal IUD market, 2021 - 2033 (USD Million)
    • 4.6.3. Nonhormonal IUD
      • 4.6.3.1. Nonhormonal IUD market, 2021 - 2033 (USD Million)
  • 4.7. Condoms
    • 4.7.1. Condoms Market, 2021 - 2033 (USD Million)
    • 4.7.2. Male Condoms
      • 4.7.2.1. Male condoms market, 2021 - 2033 (USD Million)
    • 4.7.3. Female Condoms
      • 4.7.3.1. Female condoms market, 2021 - 2033 (USD Million)
  • 4.8. Vaginal Ring
    • 4.8.1. Vaginal Ring Market, 2021 - 2033 (USD Million)
  • 4.9. Subdermal Implants
    • 4.9.1. Subdermal Implants Market, 2021 - 2033 (USD Million)
  • 4.10. Injectable
    • 4.10.1. Injectable Market, 2021 - 2033 (USD Million)
  • 4.11. Others
    • 4.11.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Company Categorization
  • 5.2. Company Market Position Analysis, 2024
  • 5.3. Strategy Mapping
    • 5.3.1. Mergers & Acquisitions
    • 5.3.2. Partnership and Collaborations
    • 5.3.3. New Product Launch
    • 5.3.4. Others
  • 5.4. Company Profiles/Listing
    • 5.4.1. Church & Dwight Co., Inc.
      • 5.4.1.1. Overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Reckitt Benckiser Group Plc
      • 5.4.2.1. Overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. Organon Group of Companies
      • 5.4.3.1. Overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Pfizer, Inc.
      • 5.4.4.1. Overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. Teva Pharmaceutical Industries Ltd.
      • 5.4.5.1. Overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. The Cooper Companies, Inc.
      • 5.4.6.1. Overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. Agile Therapeutics
      • 5.4.7.1. Overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives
    • 5.4.8. Mayer Laboratories, Inc.
      • 5.4.8.1. Overview
      • 5.4.8.2. Financial performance
      • 5.4.8.3. Product benchmarking
      • 5.4.8.4. Strategic initiatives
    • 5.4.9. Mayne Pharma Group Limited.
      • 5.4.9.1. Overview
      • 5.4.9.2. Financial performance
      • 5.4.9.3. Product benchmarking
      • 5.4.9.4. Strategic initiatives
    • 5.4.10. Bayer AG
      • 5.4.10.1. Overview
      • 5.4.10.2. Financial performance
      • 5.4.10.3. Product benchmarking
      • 5.4.10.4. Strategic initiatives
    • 5.4.11. Afaxys, Inc.
      • 5.4.11.1. Overview
      • 5.4.11.2. Financial performance
      • 5.4.11.3. Product benchmarking
      • 5.4.11.4. Strategic initiatives
    • 5.4.12. AbbVie
      • 5.4.12.1. Overview
      • 5.4.12.2. Financial performance
      • 5.4.12.3. Product benchmarking
      • 5.4.12.4. Strategic initiatives
    • 5.4.13. Gedeon Richter
      • 5.4.13.1. Overview
      • 5.4.13.2. Financial performance
      • 5.4.13.3. Product benchmarking
      • 5.4.13.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Contraceptive methods and associated side effects
  • Table 4 Classification of contraceptives by the U.S. FDA
  • Table 5 States that have expanded contraceptive coverage guarantee in the Affordable Care Act
  • Table 6 Types of oral contraceptives, composition, and regimen
  • Table 7 List of intrauterine devices currently available in the U.S.
  • Table 8 Types of male condom variants
  • Table 9 US contraceptive market revenue estimates and forecast, by product, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 U.S. contraceptive market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Market snapshot
  • Fig. 10 Segment snapshot
  • Fig. 11 Competitive landscape
  • Fig. 12 U.S. contraceptive market: Parent market outlook
  • Fig. 13 U.S. contraceptive market dynamics
  • Fig. 14 Market driver relevance analysis (Current & future impact)
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 U.S. contraceptive market: Porter's five forces analysis
  • Fig. 17 U.S. contraceptive market: PESTLE analysis
  • Fig. 18 U.S. contraceptive market: product segment dashboard
  • Fig. 19 U.S. contraceptive market: product market share analysis, 2024 & 2033
  • Fig. 20 Pills market, 2021 - 2033 (USD Million)
  • Fig. 21 Intrauterine Devices (IUD) market, 2021 - 2033 (USD Million)
  • Fig. 22 Hormonal IUD market, 2021 - 2033 (USD Million)
  • Fig. 23 Nonhormonal IUD market, 2021 - 2033 (USD Million)
  • Fig. 24 Condoms market, 2021 - 2033 (USD Million)
  • Fig. 25 Male condoms market, 2021 - 2033 (USD Million)
  • Fig. 26 Female condoms market, 2021 - 2033 (USD Million)
  • Fig. 27 Vaginal ring market, 2021 - 2033 (USD Million)
  • Fig. 28 Subdermal implants market, 2021 - 2033 (USD Million)
  • Fig. 29 Injectable market, 2021 - 2033 (USD Million)
  • Fig. 30 Others market, 2021 - 2033 (USD Million)
  • Fig. 31 Company/competition categorization
  • Fig. 32 Company market position analysis
  • Fig. 33 U.S. contraceptive market: Strategy mapping